![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMEDG RNS Number : 1605N Medgenics Inc 07 June 2010 Medgenics, Inc. ('Medgenics' or the 'Company') Directors Dealing and Block Listing interim review 7 June 2010 Medgenics was informed on 3 June 2010 that Deborah Pearlman, the spouse of Andrew Pearlman, a director of the Company, had on 31 May 2010 given notice that she wished to exercise 3,166 RW Warrants for common shares of par value of US $0.0001 each ("Common Shares") at an exercise price of US $0.0000047 per Common Share. Following the issue of said Common Shares on 3 June 2010, Andrew Pearlman is interested in 1,238,185 Common Shares representing 0.8% of the Company's issued share capital. 1. Name of company: Medgenics, Inc. 2. Name of scheme: Warrants and Options under the Company's Share Incentive Schemes 3. Period of return: From To 4 December 2009 3 June 2010 4. Number and class of securities not issued under the scheme at the beginning of the period: 6,634,015 Common Shares 5. Number of securities issued under scheme during period: 235,238 Common Shares following the due exercise of Warrants issued by the Company (213,675 Common Shares pursuant to W Warrants and 21,563 Common Shares pursuant to RW Warrants). 6. Balance under scheme of securities not yet issued at end of period: 6,398,777 Common Shares 7. Number and class of securities originally admitted and the date of admission: 20,818,683 Common Shares admitted under the block admission on 4 December 2007. Following the above issues during the period the total number of Common Shares in issue is 154,877,554 .The percentage of shares not in public hands is 29.2 per cent. There are no changes in the shareholders who hold more than three per cent of the issued share capital as previously announced on May 25, 2010. For further information, contact: Andrew Pearlman +972 4 902 8900 CEO Medgenics, Inc Mike Wort / Anna Dunphy +44 207 861 3838 De Facto Communications (PR) James Pinner / Derek Crowhurst +44 207 444 0800 Religare Capital Markets (Nomad) Ian Callaway / Alex Mattey +44 207 638 5600 SVS Securities plc (Joint Broker) Jonathan Senior +44 207 776 1219 Nomura Code (Joint Broker) Notes to Editors: About Medgenics: Medgenics is a commercial -stage biopharmaceutical Company developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The first revenue generating commercial deal with a well known multinational pharmaceutical company was negotiated in late 2009 and we look forward to generating additional deals to further commercialise the Biopump platform technology. Biopumps are made using needle biopsies taken from the lower layer of the patient's skin under local anaesthetic, and processed during 10-14 days to become 30 mm long tissue biofactories producing the required protein. The requisite number of Biopumps are injected under the patient's skin to provide sustained protein production and delivery for many months. The Company is developing the Biopump to provide substantially greater safety and reliability in protein treatment in a more cost effective manner than experienced with the existing injected protein therapies. Medgenics currently has three products in development based on this technology and addressing the indications of: - Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) - Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) - Haemophilia - using a Biopump to produce clotting Factor VIII The Company's Phase I/II clinical trial using EPODURE to treat anaemia in patients with chronic kidney disease, has demonstrated proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for six months or more, EPODURE Biopumps have already provided effective anaemia treatment in most of these patients for 6-12 months, even at the low administered dose. Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies. In addition to treatments for Anaemia, Hepatitis-C, and Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US $87 billion by 2010. Other potential applications of Biopumps producing various proteins include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity, and diabetes. This information is provided by RNS The company news service from the London Stock Exchange END RDSKKODPFBKKBAK
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions